Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2015 01:30 ET | Source: Galapagos NV

Galapagos ontwikkelt combinatietherapie voor taaislijmziekte (mucoviscidose)

GLPG2665, een volgende generatie (C2) corrector, samen met de twee andere componenten van de drievoudige combinatie, geeft een tot zesvoud groter chloride transport ten opzichte van Orkambi1) in...
October 15, 2015 01:30 ET | Source: Galapagos NV

Galapagos advances triple combination therapy in cystic fibrosis

GLPG2665, a next-generation (C2) corrector, together with the other two components of the triple combination, show up to six-fold greater chloride transport than Orkambi1) in vitroTriple combination...
October 09, 2015 01:30 ET | Source: Galapagos NV

Kandidaat taaislijmziektemedicijn GLPG1837 toont positieve Fase 1 resultaten

Mechelen, België; 9 oktober 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) presenteert vandaag Fase 1 resultaten van GLPG1837 op de North American Cystic Fibrosis Conference (NACFC) in Phoenix,...
October 09, 2015 01:30 ET | Source: Galapagos NV

Positive safety and tolerability for novel potentiator GLPG1837

Mechelen, Belgium; 9 October 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) presents today topline Phase 1 results with novel potentiator GLPG1837 at the North American Cystic Fibrosis Conference...
October 08, 2015 01:30 ET | Source: Galapagos NV

Galapagos presenteert veelbelovende bevindingen in taaislijmziekteprogramma's op NACFC 2015

Vooruitgang en diepte van de ontdekkingen en ontwikkelingen in taaislijmziekte beslaat vijf posters Mechelen, België; 8 oktober 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) vaardigt...
October 08, 2015 01:30 ET | Source: Galapagos NV

Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015

Five poster presentations cover progress and depth of discovery and development efforts in CF Mechelen, Belgium; 8 October 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) is present...
October 02, 2015 16:16 ET | Source: Galapagos NV

Galapagos raises EU1.2 million through warrant exercises

MECHELEN, Belgium, Oct. 2, 2015 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) announced a share capital increase arising from warrant exercises. As a result of warrant exercises,...
October 02, 2015 16:01 ET | Source: Galapagos NV

Galapagos haalt €1,2 miljoen op door uitoefening van warrants

Mechelen, België; 2 oktober 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) kondigt een kapitaalverhoging aan als gevolg van de uitoefening van warrants. Aansluitend op de...
October 02, 2015 16:01 ET | Source: Galapagos NV

Galapagos raises €1.2 million through warrant exercises

Mechelen, Belgium; 2 October 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced a share capital increase arising from warrant exercises. As a result of warrant exercises, Galapagos...
September 25, 2015 10:44 ET | Source: Galapagos NV

Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritis

Galapagos regains all unencumbered rights to filgotinib Filgotinib is the most selective JAK1 inhibitor Best-in-class efficacy and safety in RA in 24-week Phase 2B studies in 877 patientsPhase 3...